E

Evolution Research Group | Woodland International Research Group

Research site
(Unclaimed)
Location
910 Autumn Road, Little Rock, Arkansas, United States of America
Site insights

Top conditions

Schizophrenia (31 trials)

Depression (18 trials)

Depressive Disorder (16 trials)

Major Depressive Disorder (16 trials)

Opioid-Related Disorders (5 trials)

Top treatments

SEP-363856
KarXT
Rapastinel
Brexpiprazole
Cariprazine
Bupivacaine Hydrochloride
Aripiprazole
Rimegepant
Acetaminophen
Glucose

Parent organization

This site is a part of Evolution Research Group

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

11 of 89
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing...

Active, not recruiting
Analgesia
Drug: Acetaminophen
Drug: HTX-011

This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14...

Active, not recruiting
Post Operative Pain
Drug: Methocarbamol
Drug: Acetaminophen

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Placebo
Drug: Xanomeline and Trospium Chloride Capsules

PRF-110 is a viscous, yellowish clear oily solution of ropivacaine intended for administration into surgical sites to provide post-operative analgesi...

Enrolling
Bunion
Drug: Ropivacaine

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Invitation-only
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in d...

Active, not recruiting
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of...

Active, not recruiting
Moderate to Severe Opioid-use Disorder
Drug: Transmucosal Buprenorphine
Drug: Extended-release Buprenorphine

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 ER in pediatric ADHD patients

Active, not recruiting
Attention-Deficit/Hyperactivity Disorder
Drug: SPN-812

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting
Episodic Migraine
Drug: BOTOX
Drug: Placebo

Trial sponsors

S

Sumitomo Pharma America, Inc. (16 trials)

Otsuka logo

Otsuka (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems